Literature DB >> 15676049

Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy.

Geoffrey S Payne1, David J Collins, Peter Loynds, Graham Mould, Philip S Murphy, Andrzej S K Dzik-Jurasz, Preminda Kessar, Nazneen Haque, Masayuki Yamaguchi, Shogo Atarashi, Martin O Leach.   

Abstract

AIMS: To measure hepatic concentrations of the fluorine-containing antimicrobial, sitafloxacin, using in vivo(19)F magnetic resonance spectroscopy (MRS).
METHODS: Data were acquired from eight healthy subjects at 2, 5, 8 and 24 h following doses of 500 mg day(-1) for 5 days using a (1)H/(19)F surface coil in a 1.5T clinical MR system. Tissue water was used as a reference.
RESULTS: Estimated liver concentrations at 2 h were 15.0 +/- 4.0 microg ml(-1) (mean +/- 95% CI), compared with 3.54 +/- 0.58 microg ml(-1) in plasma (n = 6), and fell below threshold concentrations (2 microg ml(-1)) by 24 h.
CONCLUSIONS: (19)F MRS is able to detect and quantify sitafloxacin in the liver. There was no evidence for the hepatic retention of the drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676049      PMCID: PMC1884756          DOI: 10.1111/j.1365-2125.2004.02246.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects.

Authors:  J O'Grady; A Briggs; S Atarashi; H Kobayashi; R L Smith; J Ward; C Ward; D Milatovic
Journal:  Xenobiotica       Date:  2001-11       Impact factor: 1.908

2.  Gallbladder localization of (19)F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil.

Authors:  A S Dzik-Jurasz; D J Collins; M O Leach; I J Rowland
Journal:  Magn Reson Med       Date:  2000-10       Impact factor: 4.668

3.  In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.

Authors:  P Jynge; T Skjetne; I Gribbestad; C H Kleinbloesem; H F Hoogkamer; O Antonsen; J Krane; O E Bakøy; K M Furuheim; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1990-11       Impact factor: 6.875

4.  The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.

Authors:  M P Findlay; M O Leach; D Cunningham; D J Collins; G S Payne; J Glaholm; J L Mansi; V R McCready
Journal:  Ann Oncol       Date:  1993-08       Impact factor: 32.976

Review 5.  In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil.

Authors:  M P Findlay; M O Leach
Journal:  Anticancer Drugs       Date:  1994-06       Impact factor: 2.248

6.  Association of intratumoral pharmacokinetics of fluorouracil with clinical response.

Authors:  C A Presant; W Wolf; V Waluch; C Wiseman; P Kennedy; D Blayney; R R Brechner
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

  6 in total
  4 in total

Review 1.  Sitafloxacin: in bacterial infections.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

2.  Non-invasive in vivo assessment of 11β-hydroxysteroid dehydrogenase type 1 activity by 19F-Magnetic Resonance Spectroscopy.

Authors:  Brian R Walker; Ruth Andrew; Gregorio Naredo-Gonzalez; Rita Upreti; Maurits A Jansen; Scott Semple; Oliver B Sutcliffe; Ian Marshall
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

3.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

4.  Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis.

Authors:  Weerawat Manosuthi; Surasak Wiboonchutikul
Journal:  Springerplus       Date:  2016-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.